Medicare's Controversial Move: Unlocking Expensive Weight Loss Drugs for the Masses
In a groundbreaking decision, Medicare is poised to offer a select group of enrollees access to highly sought-after obesity drugs, but at a price. The Centers for Medicare and Medicaid Services (CMS) unveiled a voluntary model program where eligible beneficiaries can obtain these drugs for a mere $50 monthly fee.
Here's the catch: Medicare is legally prohibited from covering weight loss medications. However, the Trump and Biden administrations have advocated for GLP-1 drugs, claiming they are essential in combating chronic diseases. This stance has sparked intense debate.
The Trump administration brokered a deal with pharmaceutical giants Eli Lilly and Novo Nordisk to offer their weight loss drugs at a discounted rate to Medicare. The program, BALANCE, aims to enhance beneficiaries' health by increasing access to these drugs in their Medicare Part D plans, coupled with lifestyle support, while managing costs for all involved.
Dr. Mehmet Oz, CMS administrator, emphasized the initiative's goal of making weight-loss medication more accessible. The program combines cutting-edge science with healthy living to reduce costs and empower Americans to take charge of their health.
CMS will negotiate with GLP-1 drug manufacturers to secure lower prices for both Medicare and Medicaid. These negotiations will also determine eligibility criteria. Participation is voluntary for manufacturers, states, and Medicare Part D insurers.
State Medicaid agencies can join in May 2026, with Part D plans following in January 2027. However, a separate short-term demonstration program will allow Medicare beneficiaries to access GLP-1s as early as July, concluding in December 2031.
The Biden administration proposed a reinterpretation of the law to cover obesity treatment as a chronic disease, but this effort was halted by the Trump administration.
In a recent agreement, eligible Medicare enrollees will pay $50 for specific GLP-1 medications approved for obesity and diabetes, while Medicare covers the remaining $245. This arrangement facilitates expanded coverage.
The agreement includes eligibility for overweight individuals with prediabetes, cardiovascular disease, obesity with diabetes, or severe obesity with uncontrolled high blood pressure. Approximately 10% of Medicare enrollees could benefit from this expanded access.
Medicare already covers certain weight loss drugs when they are approved for treating specific medical conditions. The Trump administration assured that price reductions would make the expansion cost-neutral, whereas the Biden administration's proposal, estimated to cost Medicare $25 billion over ten years, did not include price cuts.
Eli Lilly and Novo Nordisk agreed to offer lower prices to state Medicaid programs, but timing varies depending on negotiations with each state. While some states have embraced this, others, like North Carolina and Michigan, are reducing or restricting coverage due to the high costs.
The Alliance of Community Health Plans, representing local insurers, seeks more details, including insurer costs. They highlighted that while GLP-1 medications can improve health, they also carry side effects that may cause patients to discontinue use within a year.
The alliance expressed its commitment to collaborating with the administration on affordable weight loss therapies. With over 70% of US adults classified as obese or overweight, the need to address this issue is more critical than ever, according to CMS.
